The American Journal of Managed Care1h
Pursuit of ADCs in Bladder Cancer Comes With Questions About Toxicity, Cost
The American Journal of Managed Care provides insights into the latest news and research in managed care across multimedia ...
The American Journal of Managed Care12h
Analysis Looks at Benefits, Toxicity of ADC Combinations in Advanced Bladder Cancer
Casas, MD, discusses a systematic review of recent trials examining objective response rate and adverse events of antibody drug conjugate (ADC) combinations in advanced urothelial cancer.
Science Daily18h
Innovative dual-target drug may lead to new investigational approach for breast cancer patients
Results from a new study published in Clinical and Translational Immunology found that dual-target antibody therapy can enhance cancer-fighting T cells more effectively than current single-target ...
AstraZeneca reports positive results for Imfinzi MIBC regimen
AstraZeneca (NASDAQ:AZN) has reported positive results from an analysis of its NIAGARA Phase 3 study of Imfinzi in the treatment of muscle-invasive bladder cancer, or MIBC. The analysis showed that ...
AstraZeneca's Imfinzi Perioperative Regimen Shows Improved Survival Outcomes In Bladder Cancer Patients
AstraZeneca's Imfinzi perioperative regimen improved survival outcomes in muscle-invasive bladder cancer, with FDA Priority ...
Scientists propose CDK2 enzyme as new target for cancer therapy
An enzyme called cyclin-dependent kinase 2 (CDK2) regulates the cell cycle and may have the potential to drive therapeutic ...